Little evidence for any direct impact of national cancer policies on short-term survival in England

March 14, 2018

A study published by The BMJ today finds little evidence for any direct impact of national cancer policy initiatives implemented since 2000 on short term cancer survival in England.

And no evidence was found for a reduction in social and economic inequalities ("deprivation gap") in cancer survival since the mid-1990s. The researchers say these findings "emphasise that socioeconomic inequalities in survival remain a major public health problem for a healthcare system founded on equity."

Cancer survival in England has been improving steadily since the 1970s, but still lags behind that seen in comparable countries in Europe. Differences in cancer survival between less and more deprived patients also persist for most types of cancer.

The NHS Cancer Plan was launched in 2000 in a bid to tackle these inequalities and improve cancer survival to levels comparable with the rest of Europe. Since then, other strategies have been introduced, but little is known about their impact at a national level.

So researchers in the Cancer Survival Group at the London School of Hygiene & Tropical Medicine set out to assess the impact of the NHS Cancer Plan and subsequent strategies on cancer survival in England and whether any gains were evenly distributed across the socio-economic groups of the population.

They analysed national cancer registry data for 3.5 million people aged 15-99 who had been diagnosed with one of the 24 most common cancers in three pre-defined calendar periods: 1996-2000, 2001-05, and 2006-13 with follow-up to 2014. This allowed comparison of trends before and after introduction of the NHS Cancer Plan.

They then estimated one year net survival for each cancer by sex, year of diagnosis, and level of deprivation. They focused on one year survival because most inequalities in cancer survival in England arise shortly after diagnosis.

They found that one year survival improved steadily from 1996 for 26 of 41 sex-cancer combinations studied. For nine additional cancers, improvement in survival was initially negligible, and really began or accelerated only later, from 2001 or 2006.

The largest improvements (greater than 1% per year) were seen for cancers that were of poor or intermediate prognosis in the 1990s, such as cancers of the oesophagus and liver in men, lung in women, and kidney, mesothelioma, and myeloma.

In contrast, survival for men diagnosed as having cancer of the larynx or testis, or Hodgkin lymphoma, was already high in the 1990s, and this improved little by 2013.

Meanwhile, the deprivation gap remained unchanged for most cancers, with a clear, persistent pattern of lower survival among more deprived patients. While the gap narrowed slightly for some cancers, where one year survival was already more than 65% in 1996, it widened notably for brain tumours in men and for lung cancer in women.

The researchers point to some limitations and say their study may be too early to detect the full impact of recently implemented cancer initiatives. Nevertheless, the study is based on virtually all cancer cases registered in England over 18 years, allowing for more accurate estimates of trends.

"Even though increasing cancer survival and reducing inequalities in survival have been among the main targets of national cancer policy initiatives implemented since 2000, this study found little evidence of a direct impact of these strategies on one year survival, and no evidence for a reduction in socioeconomic inequalities in survival," write the authors.

They say their findings "should be taken into consideration by cancer policy makers and inform future initiatives" and suggest that "shifting the focus from individual factors to healthcare system factors might prove to be beneficial in improving cancer outcomes among the most disadvantaged."

Does this mean the NHS cancer reforms failed, ask researchers at the University of Otago, New Zealand, in a linked editorial?

They point out that drivers of social disparities in cancer outcomes are complex, making it difficult to establish cause and effect, and they say genuine improvements "may require a more comprehensive approach than the NHS reforms."

To reduce the incidence and impact of cancer "we must continue to be ambitious," they write. "The goals of the NHS Cancer Plan were to save lives and to ensure that the gains were evenly shared. These goals remain critical. The methods to achieve them need more work," they conclude.


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to